22 results about "Antigens present" patented technology

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.

The present invention provides novel antigens of an allergy to fish, methods and kits for diagnosing an allergy to fish, pharmaceutical compositions comprising such an antigen, fishes, fish eggs or processed products of such fish or fish egg in which such an antigen is eliminated, fishes that deliver such fish eggs or are born from such fish egg, and a tester for determining the presence or absence of a fish antigen in an object of interest. The present invention also relates to polypeptides comprising an epitope of an antigen, kits, compositions and methods for diagnosing an allergy, comprising such a polypeptide, pharmaceutical compositions comprising such a polypeptide, and raw materials or processed products in which an antigen comprising such a polypeptide is eliminated or reduced. The present invention further relates to a tester for determining the presence or absence of an antigen in an object of interest.

A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided

The invention relates to the field of immune cells. According to the preparation method and application of the novel immune cell, lentivirus containing DNA molecules subjected to gene modification is used for transfecting cells in peripheral blood of mammals, so that the cells can be passaged for multiple times, and the cells have the antigen presenting capacity and the capacity of activating and amplifying natural killer cells. After the cell is further genetically modified, better transmembrane transfer, antigen presentation and natural killer cell activation can be realized. After gene modification, the cell and different cytokines or small molecules jointly activate and amplify mononuclear cells to obtain a larger number of natural killer cells with higher purity, epigenetics are regulated and controlled to change the receptor and ligand expression quantity of the natural killer cells, and then the cytotoxicity of effector cells is improved. The invention can be used for preparing antigen presenting cells and CTL cells aiming at different antigens and an application method. The cells and the using method have wide application prospects in the aspects of prevention and treatment of tumors and infectious diseases.

The present invention relates to in vitro methods of producing mature dendritic cells, a dendritic cell maturation cocktail, a method of producing mature antigen presenting dendritic cells in vitro, methods of manufacturing vaccines containing mature dendritic cells, antigen-presenting mature dendritic cells produced according to the methods described, vaccines containing the mature antigen-presenting dendritic cells and methods of treatment and used of mature antigen-presenting cells of the invention.

Disclosed are immune cell enhancers containing a first moiety that binds a cytokine receptor on the immune cell, and a second moiety that binds a co-stimulatory receptor on the immune cell. Also disclosed are adoptive cell therapeutic systems. The system includes a) a chimeric antigen receptor (CAR) immune cell comprising a CAR that comprises an extracellular domain that binds an antigen present on a cancer cell, a transmembrane domain, and an endodomain comprising a co-stimulatory region, but not a stimulatory region comprising a CD3 protein and b) a CAR-enhancer comprising a first moiety that binds an extracellular domain on the CAR immune cell and a second moiety that binds a cytokine receptor on the immune cell and uses thereof to treat cancer. Further disclosed are pharmaceutical compositions containing an effective amount of the ICE or the system and a pharmaceutically acceptable carrier. And methods of treating cancer therewith.

(1) The purpose of the present invention is to provide an anti-tumor agent having an improved immune checkpoint inhibitor effect. (2) The purpose of the present invention is also to provide a drug which can exert an effect even in the absence of an antigen. (1) An antitumor agent formed by combining an immune checkpoint inhibitor and a liposome composition containing an NKT cell ligand. And (2) a liposome composition containing an NKT cell ligand and an antigen.

The invention discloses a space-time controllable activated vaccine adjuvant, a vaccine as well as preparation methods and applications of the space-time controllable activated vaccine adjuvant and the vaccine. The vaccine adjuvant disclosed by the invention is formed by co-assembling polypeptide, a light / sound sensitive agent and a congenital immune signal agonist. The space-time controllable activated vaccine adjuvant disclosed by the invention can further entrap multiple disease type antigens to prepare a vaccine, controls and activates an antigen presenting cell innate immune signal channel through exogenous near-infrared light / ultrasound, induces I-type interferon secretion and enhances the antigen presenting efficiency so as to activate strong antigen specific cellular immune and humoral immune response, and can be used for preparing the vaccine. Therefore, tumor growth and metastasis are effectively inhibited, and the compound is expected to be further applied to prevention of infectious diseases.

This document provides method and materials for treating cancer. In some cases, methods and materials for treating estrogen receptor negative (ER-) cancers (e.g., ER- breast cancers such as triple-negative breast cancers (TNBCs)) are provided. For example, one or more endoxifen (ENDX) compounds can be administered to a mammal (e.g., a human) having an ER- cancer (e.g., an ER- breast cancer such as a TNBC) to treat that mammal. For example, one or more ENDX compounds and one or more agents / therapies that can alter the antigens presented on the surface of a cancer cell can be administered to a mammal (e.g., a human) having an ER+ cancer and / or an ER- cancer (e.g., an ER- breast cancer such as a TNBC) to treat that mammal.

Described herein are antibodies and immunoconjugates capable of targeting antigens within the kidney. The antibodies described herein generally a polypeptide, wherein the polypeptide comprises: an antigen-binding domain (e.g., immunoglobulin single-chain domain antibody) and a Fc domain, wherein the antigen-binding domain binds an antigen present within the kidney.

Aspects of this invention relate to a novel monoclonal antibody specifically designed to exhibit selective binding affinity towards antigens present predominantly in X chromosome sperm. The antibody is engineered for applications to sex select sperm for cattle breeding purposes.

This invention relates to a T-cell receptor capable of binding to the HPV16 E6 antigen presented by the HLA-C*14:02 molecule. The T-cell receptor comprises: αCDR1 (amino acid sequence as shown in SEQ ID NO:1), αCDR2 (amino acid sequence as shown in SEQ ID NO:3), αCDR3 (amino acid sequence as shown in SEQ ID NO:5), βCDR1 (amino acid sequence as shown in SEQ ID NO:11), βCDR2 (amino acid sequence as shown in SEQ ID NO:13), and βCDR3 (amino acid sequence as shown in SEQ ID NO:15). This invention provides a novel and precise immunotherapy strategy for patients with HLA-C*14:02 genotype HPV-related cervical cancer, significantly expanding the applicable population for TCR-T therapy.

To provide a test kit that enables intuitive understanding of the time required to determine the presence or absence of an antigen. [Solution] A test kit 100 for testing for the presence or absence of an antigen, comprising a collection member 110 for collecting a specimen from a subject, a reagent container 120 containing a liquid reagent L1 capable of extracting antigens from the specimen and for producing a mixed liquid of the specimen and the liquid reagent L1, a determination member 130 for determining the presence or absence of the antigen from the mixed liquid, a timer member S2, and an individual packaging box 190, wherein the timer member S2 is a bottomed cylindrical body having a bottom portion at one end and an opening at the other end, and comprising a staining liquid container 160 containing staining liquid L2, and a sheet member 180 which can be inserted into the staining liquid container 160 from the opening and whose length from one end to the other end is longer than the length from the bottom portion to the opening, wherein the sheet member 180 is characterized in that when one end of the sheet member 180 is immersed in staining liquid L2, the staining liquid L2 penetrates to the other end and changes color.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.

The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.

The invention relates to the technical field of biomedical engineering, in particular to a ginsenoside Rk1 activated double-targeting cancer cell membrane nano vaccine as well as a preparation method and application thereof. Pharmacological regulation is performed on cancer cells through Rk1, the membrane surface antigen spectrum of the cancer cells is remarkably remodeled, the expression of tumor associated antigen (TAA) is enhanced, an immunosuppressive molecule CD47 is down-regulated, and an antigen presenting molecule MHC-I is up-regulated. CpG oligodeoxynucleotide is loaded on a zeolite imidazate framework material ZIF-8, and then the zeolite imidazate framework material ZIF-8 is coated with a cancer cell membrane to form a core-shell structure, so that accurate and acid-sensitive responsive release is realized. The nano vaccine can significantly improve the antigen uptake and activation efficiency of dendritic cells (DC), and enhance the immune effect and immune memory formation of CD8T cells. Animal experiments show that the nano vaccine shows about 80% of tumor inhibition rate in a 4T1 mouse breast cancer model, and has good immune activation ability and anti-tumor efficacy.

Technologies for the prevention and / or treatment of Shigella infections.

Compositions containing lipid nanoparticles and nucleic acid therapeutic agents are disclosed. For example, calcium phosphate nanoparticles having a lipid coating are provided, wherein the calcium phosphate nanoparticles include a cyclic dinucleotide and the lipid coating includes phosphatidylserine. The compositions can be formulated for administration to the lungs of a subject via inhalation, or for administration via injection. Methods for the treatment of lung cancer and other cancers are also described. Targeted delivery of therapeutic agents such as cyclic dinucleotides to antigen presenting immune cells via the disclosed methods can elicit beneficial antitumor immunity.

Technologies for the prevention and / or treatment of pathogenic or microbial infections. Compositions relate to compositions, vaccines and methods comprising an immunogenic multiple antigen presenting system (MAPS), where two or more biotinylated polysaccharide antigens are interconnected or joined together by one or more fusion proteins comprising (i) a sialic acid binding domain (SBD) and (ii) a biotin-binding moiety (BBM), thereby facilitating the joining multiple polysaccharide antigens together in the complex to form a cross-linked MAPS-X immunogenic complex. The polysaccharide antigens that are linked can be on the same polysaccharide macromolecule or on distinct polysaccharide macromolecules.

The invention provides a method for the expansion of anti-tumor T-cells, comprising the steps of:a) providing a phagocytosable particle, having one or more tumor neoantigenic constructs tightly associated thereto, wherein the tumor neoantigenic construct comprises an amino-acid sequence comprising at least one mutated amino acid known or suspected to be associated with a cancer in a subject, or a mutated or non-mutated amino-acid sequence known or suspected to be expressed in a cancer cell in the subject;b) providing a viable antigen-presenting cell;c) contacting the particle with the antigen-presenting cell in vitro under conditions allowing phagocytosis of the particle by the antigen-presenting cell;d) providing a T-cell sample comprising viable T-cells from the subject;e) contacting the T-cell sample with the antigen-presenting cell contacted with the particle in vitro under conditions allowing specific activation of anti-tumor T-cells in response to antigen presented by the antigen-presenting cell.The invention also provides tumor neoantigenic constructs as defined in the specification.

Disclosed are immune cell enhancers containing a first moiety that binds a cytokine receptor on the immune cell, and a second moiety that binds a co-stimulatory receptor on the immune cell. Also disclosed are adoptive cell therapeutic systems. The system includes a) a chimeric antigen receptor (CAR) immune cell comprising a CAR that comprises an extracellular domain that binds an antigen present on a cancer cell, a transmembrane domain, and an endodomain comprising a co-stimulatory region, but not a stimulatory region comprising a CD3 protein and b) a CAR-enhancer comprising a first moiety that binds an extracellular domain on the CAR immune cell and a second moiety that binds a cytokine receptor on the immune cell and uses thereof to treat cancer. Further disclosed are pharmaceutical compositions containing an effective amount of the ICE or the system and a pharmaceutically acceptable carrier. And methods of treating cancer therewith.

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.